| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1572-0241.2007.01201.X |
| P698 | PubMed publication ID | 17403072 |
| P50 | author | Maria Rosaria Capobianchi | Q28743735 |
| Giuliano Tocci | Q37829220 | ||
| Enrico Girardi | Q42272530 | ||
| Francesco Vairo | Q47502465 | ||
| P2093 | author name string | Claudio Angeletti | |
| Giorgio Antonucci | |||
| Ubaldo Visco Comandini | |||
| Pasquale Noto | |||
| Maria Antonella Longo | |||
| Evangelo Boumis | |||
| Alessandra Oliva | |||
| Maria Carmela Solmone | |||
| P2860 | cites work | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| Effect of aging on T lymphocyte activation | Q33846360 | ||
| Ageing of lymphocytes and lymphocytes in the aged | Q34079338 | ||
| Age-related changes in lymphocyte development and function | Q34293466 | ||
| Altered T cell signalling in ageing | Q34340571 | ||
| Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? | Q34537738 | ||
| Chronic hepatitis C virus infection in older adults | Q36305517 | ||
| The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. | Q40445497 | ||
| Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study | Q42989003 | ||
| Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. | Q42990813 | ||
| Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. | Q42993387 | ||
| Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan | Q42995254 | ||
| Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group | Q42996746 | ||
| Incident hepatitis C virus infection in a community-based population in Japan | Q43036614 | ||
| Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. | Q43659671 | ||
| Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. | Q45006616 | ||
| Factors contributing to ribavirin-induced anemia | Q45105371 | ||
| Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients | Q45733443 | ||
| The pattern of T lymphocyte differentiation is altered during thymic involution | Q46503525 | ||
| Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. | Q50577281 | ||
| Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C | Q58099679 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ribavirin | Q421862 |
| P304 | page(s) | 1383-1391 | |
| P577 | publication date | 2007-03-31 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. | |
| P478 | volume | 102 |
| Q34226904 | A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: association study with mutations in the core and NS5A region of hepatitis C virus |
| Q34067956 | Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection |
| Q37130025 | Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection |
| Q37879193 | Antiviral therapy: why does it fail in HCV-related chronic hepatitis? |
| Q36716281 | Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. |
| Q36690763 | Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis |
| Q34032909 | CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection |
| Q38198992 | Chronic hepatitis C in the aged: much ado about nothing or nothing to do? |
| Q50549693 | Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C. |
| Q42066336 | Cryoglobulinemia in elderly patients with HCV-related chronic hepatitis |
| Q45971639 | Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. |
| Q50524187 | Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. |
| Q40629289 | Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. |
| Q33938574 | Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study |
| Q42979106 | Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. |
| Q50550604 | Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. |
| Q42269830 | Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients |
| Q38501726 | Hepatitis C Infection in the Elderly |
| Q34178971 | Hepatitis C in the elderly: epidemiology, natural history, and treatment |
| Q35783876 | Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens |
| Q37053802 | Hepatitis C virus infection in the elderly: epidemiology, natural history and management |
| Q38056077 | Host factors determining the efficacy of hepatitis C treatment. |
| Q36238748 | Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study |
| Q30500804 | Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials |
| Q38741305 | Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease |
| Q38311383 | Long-term pegylated interferon-α-2a treatment for chronic hepatitis C in an elderly renal transplant recipient: case report and literature review |
| Q43974244 | Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C. |
| Q37727164 | Management of nonresponsive hepatitis C. |
| Q50562095 | Older age per se has negative effect on hepatitis C patients treated with peginterferon and ribavirin. |
| Q38295819 | Optimal management of patients with chronic hepatitis C and comorbidities. |
| Q41143949 | Optimum predictors of therapeutic outcome in HCV patients in Pakistan |
| Q30733177 | Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations |
| Q34134940 | Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C |
| Q50558655 | Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. |
| Q38160178 | Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis |
| Q51852531 | Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. |
| Q37798474 | Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital |
| Q40143308 | Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management |
| Q40707649 | Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. |
| Q60914519 | Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C |
| Q33834958 | The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings |
| Q34190390 | The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients |
| Q39112435 | The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. |
| Q40707621 | The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study |
| Q38243001 | Treating hepatitis C in the elderly: the future is near? |
| Q50558388 | Treatment Uptake of Patients with Chronic Hepatitis C: Can We Expect and Do More? |
| Q59351904 | Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study |
| Q37693926 | Treatment of chronic hepatitis C in elderly patients |
| Q43048213 | Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors |
Search more.